0HAV Stock Chart & Stats
$156.52
$2.26(1.64%)
At close: 4:00 PM EDT
$156.52
$2.26(1.64%)
Day’s Range― - ―
52-Week Range$107.66 - $179.00
Previous CloseN/A
Volume2.53K
Average Volume (3M)1.96K
Market Cap
$49.35B
Enterprise Value$41.35K
Total Cash (Recent Filing)$1.76B
Total Debt (Recent Filing)$3.95B
Price to Earnings (P/E)33.9
Beta0.95
Next Earnings
Nov 30, 2026EPS Estimate
1.73Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)5.09
Shares Outstanding281,928,860
10 Day Avg. Volume2,192
30 Day Avg. Volume1,958
Financial Highlights & Ratios
PEG Ratio9.44
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$177.71Price Target Upside13.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)6.2
Revenue Forecast (FY)$7.50B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring Revenue ModelAgilent combines high-value instrument sales with repeat consumables, service contracts, software, and workflow integration. This diversified model can deepen customer relationships, increase lifetime revenue per account, and provide recurring demand beyond capital-equipment replacement cycles.
Strong Cash GenerationRobust free cash flow and high conversion from earnings provide internal funding for research, product launches, capital returns, and debt management. This cash-generation strength improves financial resilience and gives Agilent flexibility to pursue growth while supporting shareholder distributions.
Improving Organic Growth And DemandRaised organic guidance, sustained order demand, and a book-to-bill ratio above one indicate improving customer activity rather than reliance solely on pricing or currency. Continued growth could support instrument placements and later consumables and service pull-through.
Bears Say
Gross-margin CompressionThe sharp gross-margin decline signals pressure from product mix, pricing, or costs and creates uncertainty around margin durability. Even with expected operating-margin expansion, a persistently lower gross-margin base could limit earnings leverage and reduce upside from revenue growth.
Higher Debt Reduces FlexibilityDebt has increased while the business faces margin and end-market variability, reducing room to absorb weaker operating conditions. Higher leverage can constrain capital allocation, increase financing exposure, and make it harder to fund investments or shareholder returns through a downturn.
Operating-cash-flow Conversion DragAlthough free cash flow is strong, operating cash flow has not consistently matched accounting earnings, suggesting working-capital or timing effects. If this pattern persists, quarterly cash generation may be more volatile and could weaken the reliability of internally funded growth and capital returns.
0HAV FAQ
What was Agilent’s price range in the past 12 months?
Agilent lowest share price was $107.66 and its highest was $179.00 in the past 12 months.
What is Agilent’s market cap?
Agilent’s market cap is $49.35B.
When is Agilent’s upcoming earnings report date?
Agilent’s upcoming earnings report date is Nov 30, 2026 which is in 60 days.
How were Agilent’s earnings last quarter?
Agilent released its earnings results on Aug 26, 2026. The company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.488 by $0.132.
Is Agilent overvalued?
According to Wall Street analysts Agilent’s price is currently Undervalued.
Does Agilent pay dividends?
Agilent pays a Quarterly dividend of $0.255 which represents an annual dividend yield of 0.58%. See more information on Agilent dividends here
What is Agilent’s EPS estimate?
Agilent’s EPS estimate is 1.73.
How many shares outstanding does Agilent have?
Agilent has 281,928,860 shares outstanding.
What happened to Agilent’s price movement after its last earnings report?
Agilent reported an EPS of $1.62 in its last earnings report, beating expectations of $1.488. Following the earnings report the stock price went up 2.495%.
Which hedge fund is a major shareholder of Agilent?
Currently, no hedge funds are holding shares in GB:0HAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$177.71 (13.54% Upside)
$177.71 (13.54% Upside)
Blogger Sentiment
Bullish
GB:0HAV Sentiment 77%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.05%
12-Months-Change
Fundamentals
Return on Equity
0.58%
Trailing 12-Months
Asset Growth
14.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agilent
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
0HAV Company Deck
0HAV Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.View all GB:0HAV earnings summaries0HAV Revenue Breakdown
39.23% Life Sciences and Diagnostics Markets
41.85% Agilent CrossLab
18.91% Applied Markets

0HAV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$177.71
▲(13.54% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month








